BDX Stock Recent News
BDX LATEST HEADLINES
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company BDX are reporting robust financial performances that highlight their resilience and strategic adaptability. The company's stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton, Dickinson and Company (NYSE:BDX ) Q3 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Christopher J. DelOrefice - Executive VP & CFO Greg Rodetis - Senior VP, Treasurer & Head of Investor Relations Thomas E.
Becton Dickinson (BDX) came out with quarterly earnings of $3.68 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $3.5 per share a year ago.
Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.
Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organic GAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectively GAAP and adjusted gross margin up 160 basis points and 50 basis points, respectively, driven by BD Excellence GAAP and adjusted operating income up 46.6% and 11.3%, respectively Company raises full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an $0.18 increase to 9.4% growth at the midpoint, while reaffirming organic revenue growth guidance1 Expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025 FRANKLIN LAKES, N.J. , Aug. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 third quarter, which ended June 30, 2025.
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
FRANKLIN LAKES, N.J. , Aug. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Urology and Critical Care (UCC) and Surgery business units are the first in the medical technology industry to achieve a diamond-level rating for all seven supply chain resilience domains of the Healthcare Industry Resilience Collaborative's (HIRC) Resiliency Badging program.
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.